Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$1.30 USD
-0.03 (-2.26%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.31 +0.01 (0.77%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Acrivon Therapeutics, Inc. has a market cap of $41.70M, which represents its share price of $1.33 multiplied by its outstanding shares number of 31.35M. As a small-cap company, ACRV's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ACRV 1.30 -0.03(-2.26%)
Will ACRV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
Can Centene Beat Q1 Earnings Estimates on Growing Premiums?
Other News for ACRV
Acrivon Therapeutics Holds Annual Stockholders Meeting
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
Acrivon Therapeutics, Inc. (ACRV) was downgraded to a Hold Rating at JonesTrading